Revolution Medicines price target raised to $60 from $55 at Oppenheimer
The Fly

Revolution Medicines price target raised to $60 from $55 at Oppenheimer

Oppenheimer analyst Jay Olson raised the firm’s price target on Revolution Medicines (RVMD) to $60 from $55 and keeps an Outperform rating on the shares after the company provided clinical updates on ‘6236 and ‘9805 in PDAC at the triple meeting and hosted an investor event. Oppenheimer is “delighted” the updated ‘6236 Phase 1 data further improved with first reported mOS data strengthening the treatment paradigm-shifting potential of ‘6236 in 2L+ PDAC. The firm is also encouraged by the FIH data of ‘9805 in PDAC, showing encouraging signs of clinical activity and favorable safety profile that surpass expectations.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App